▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #4145 by analyst upside · 2026-10-16
AMGN
Amgen Inc.
Healthcare · Market Cap $235B · P/E 27.0x
ANALYST PRICE TARGET
-9.0%
implied upside to consensus target
Current Price $434.03
Consensus Target $394.98
Bull Target $500.0
Bear Target $225.0
Analysts Covering 29
ANALYST CONSENSUS - HOLD
Strong Buy
3
Buy
7
Hold
14
Sell
5
52-Week Low $288.0
52-Week High $447.03
YTD Return +35.2%
FUNDAMENTALS
Market Cap $235B
P/E Ratio (TTM) 27.0x
Forward P/E 17.7x
EPS (TTM) $16.10
PEG Ratio 2.54
Dividend Yield 2.32%
Revenue (TTM) $38.1B
Profit Margin 23.0%
52-WEEK RANGE
52-Week Low $288.0
52-Week High $447.03
Current Price $434.03
Bear Target $225.0
Bull Target $500.0
● Now $434.03 ● Target $394.98
TRADING DATA
Avg Volume 2.8M
YTD Return +35.2%
Analyst Count 29
Consensus Hold
Upside to Target -9.0%
Last Updated 2026-10-16

ANALYST SUMMARY

Amgen Inc. (AMGN) is currently trading at $434.03 with a Wall Street consensus price target of $394.98, which is 9.0% below the current price over the next 12 months. 29 analysts currently cover AMGN, with a consensus rating of Hold - 34% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $500.0, while the most cautious has a target of $225.0.

AMGN operates in the Healthcare sector with a market capitalisation of $235B. The stock is up 35.2% year-to-date and is currently trading near the upper end of its 52-week range of $288.0 – $447.03.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

TMO -1.1%
Thermo Fisher Scientific Inc.
$258B · P/E 37.5x · Buy
ABT +15.3%
Abbott Laboratories
$181B · P/E 33.8x · Buy
NVS +2.8%
Novartis AG
$286B · P/E 22.7x · Buy
ISRG +11.8%
Intuitive Surgical, Inc.
$151B · P/E 49.1x · Buy
AZN +24.3%
AstraZeneca PLC
$259B · P/E 23.9x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for AMGN, with each firm's 90-day track record across all stocks we track. See full firm rankings →

UBS - Reiterated
Buy → Buy 2026-10-09 33% win rate (6 calls)
RBC Capital - Reiterated
Outperform → Outperform 2026-10-08 Building track record
Cantor Fitzgerald - Reiterated
Neutral → Neutral 2026-10-08 40% win rate (10 calls)
Truist Securities - Reiterated
Hold → Hold 2026-10-07 Building track record
Morgan Stanley - Reiterated
Equal-Weight → Equal-Weight 2026-10-07 Building track record
Scotiabank - Reiterated
Sector Outperform → Sector Outperform 2026-09-29 20% win rate (5 calls)
HSBC ↓ Downgrade
Buy → Hold 2026-09-10 Building track record
BMO Capital ↓ Downgrade
Outperform → Market Perform 2026-09-08 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
45
out of 100
Coverage depth
26/30
Consensus clarity
17/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →